Droxidopa
Adrenergic and Dopaminergic Agents
- Drug class
- Adrenergic and Dopaminergic Agents
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 3
- FDA reports (12 mo)
- 264
Overview
Plain-language summary, compiled from the cited regulatory records
Droxidopa is a medication classified as an adrenergic and dopaminergic agent [1]. It is approved for treating symptomatic neurogenic orthostatic hypotension (nOH) in adult patients [1]. This condition can cause dizziness, lightheadedness, or a feeling of impending blackout [1]. Droxidopa is indicated for nOH that results from primary autonomic failure, including Parkinson's disease, multiple system atrophy, and pure autonomic failure [1]. It is also used for nOH caused by dopamine beta-hydroxylase deficiency and non-diabetic autonomic neuropathy [1]. The effectiveness of droxidopa beyond two weeks of treatment has not been established [1].
In the past 12 months, there have been 264 adverse event reports associated with droxidopa [2]. The most frequently reported adverse events include death, dizziness, falls, hallucinations, and aggravation of the condition [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | January 25, 2024 |
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Droxidopa capsules indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of droxidopa capsules should be assessed periodically. Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Drug interactions
Known interactions involving Droxidopa. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 049f997b-1649-46… · revised March 28, 2023 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.